0001493152-18-003551.txt : 20180319 0001493152-18-003551.hdr.sgml : 20180319 20180319120117 ACCESSION NUMBER: 0001493152-18-003551 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20180319 FILED AS OF DATE: 20180319 DATE AS OF CHANGE: 20180319 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Biofrontera AG CENTRAL INDEX KEY: 0001712641 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: 2M FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38396 FILM NUMBER: 18697955 BUSINESS ADDRESS: STREET 1: HEMMELRATHER WEG 201 CITY: LEVERKUSEN STATE: 2M ZIP: D-51377 BUSINESS PHONE: 011 49 214 876 00 MAIL ADDRESS: STREET 1: HEMMELRATHER WEG 201 CITY: LEVERKUSEN STATE: 2M ZIP: D-51377 6-K 1 form6-k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO

RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of March 2018

Commission File Number: 001-38396

BIOFRONTERA AG

(Registrant’s name / Translation of registrant’s name into English)

Hemmelrather Weg 201, D-51377 Leverkusen Germany

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [X] Form:40-F [ ]

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): N/A

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): N/A

EXHIBITS

Exhibit Number		Description

99.1		Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act]

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BIOFRONTERA AG

	By:	/s/ Hermann Lübbert
	Name:	Hermann Lübbert
	Title:	Chief Executive Officer

	By:	/s/ Thomas Schaffer
	Name:	Thomas Schaffer
	Title:	Chief Financial Officer

Date: March 19, 2018

EX-99.1 2 ex99-1.htm

Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act]

Publication pursuant to § 43 WpHG

Maruho Co. Ltd., Osaka, Japan and Maruho Deutschland GmbH, Leverkusen (together the “Notifiers”), informed Biofrontera AG on 16 March 2018, with reference to notifications pursuant to sections 33, 34, 37 WpHG (German Securities Trading Act) dated 19 February 2018 and 01 March 2018, in which they communicated that their voting interest in Biofrontera had changed from 7.97% to 16.82% effective 15 February and from 14.60% to 20.096% effective 26 February 2018, in accordance with section 43 WpHG para (1) as follows:

	1.	The (re)acquisition of voting rights took place in the course of the settlement of a securities loan. The Notifiers confirm their long-term strategic commitm.ent to the Issuer.

	2.	The Notifiers currently do not intend to acquire or otherwise obtain any further voting rights within the next twelve months

	3.	the Notifiers are not currently seeking to exert any influence on the composition of the administrative, management and supervisory bodies of the issuers

	4.	The Notifiers are not currently seeking to make any material changes to the issuer’s capital structure, in particular with regard to the ratio of equity to debt financing and the dividend policy.

	5.	Since the (re)acquisition of voting rights took place in the course of fulfilling a securities loan, no (financial) funds were used for the acquisition.

Anke zur Mühlen

Investor Relations Manager

Biofrontera AG

Hemmelrather Weg 201

D-51377 Leverkusen

www.biofrontera.com

T: +49 (0) 214 87632 22

F: +49 (0) 214 87632 90

E-Mail: a.zurmuehlen@biofrontera.com

Vorstand:

Prof. Dr. Hermann Lübbert, CEO

Christoph Dünwald, CCO

Thomas Schaffer, CFO

Aufsichtsratsvorsitz:

Dr. Ulrich Granzer

Amtsgericht Köln, HRB 49717

Diese E-Mail und etwa anhängende Dateien enthalten vertrauliche Informationen und sind ausschließlich für den Adressaten bestimmt. Sollten Sie diese E-Mail irrtümlich erhalten haben, informieren Sie uns hierüber bitte unter a.zurmuehlen@biofrontera.com oder unter der oben angegebenen Telefonnummer, und löschen Sie diese E-Mail einschließlich etwa angehängter Dateien aus Ihrem System. Bitte beachten Sie, dass die Weitergabe, Kopie und sonstige unautorisierte Nutzung der E-Mail und etwa angehängter Dateien verboten sind. Vielen Dank.

This e-mail and any files transmitted with it are confidential and intended solely for the use of the individual or entity to whom they are adressed. If you have received this e-mail in error please notify a.zurmuehlen@biofrontera.com or contact Biofrontera under the phone number specified above and delete this e-mail including attachments from your system. Please note that any unauthorised review, copying, disclosing or other use whatsoever are prohibited. Thank you.

Belixos medical skin care: